Takeda Discontinues TAK-128 Clinical Program For Peripheral Diabetic Neuropathy
This article was originally published in The Pink Sheet Daily
Executive Summary
Japanese firm simultaneously announces that it has inked a monoclonal antibody discovery deal with Xoma.